Država: Kanada
Jezik: angleščina
Source: Health Canada
AMITRIPTYLINE HYDROCHLORIDE
AA PHARMA INC
N06AA09
AMITRIPTYLINE
10MG
TABLET
AMITRIPTYLINE HYDROCHLORIDE 10MG
ORAL
100/1000
Prescription
TRICYCLICS AND OTHER NOREPINEPHRINE-REUPTAKE INHIBITORS
Active ingredient group (AIG) number: 0101524001; AHFS:
APPROVED
2010-08-03
_ELAVIL_ _®_ _ (amitriptyline hydrochloride) _ _Page 1 of 43_ PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION PR ELAVIL ® Amitriptyline hydrochloride tablets Tablets, 10 mg, 25 mg, 50 mg and 75 mg, Oral USP Antidepressant AA PHARMA INC. 1165 Creditstone Road Unit #1 Vaughan, Ontario L4K 4N7 www.aapharma.ca Date of Initial Authorization: April 28, 1975 Date of Revision: May 09, 2023 Submission Control Number: 268308 _ _ _ELAVIL_ _®_ _ (amitriptyline hydrochloride) _ _Page 2 of 43_ RECENT MAJOR LABEL CHANGES 3 SERIOUS WARNINGS AND PRECAUTIONS BOX 05/2023 7 WARNINGS AND PRECAUTIONS 05/2023 7 WARNINGS AND PRECAUTIONS, 7.1.1 Pregnant Women 05/2023 TABLE OF CONTENTS SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF AUTHORIZATION ARE NOT LISTED. RECENT MAJOR LABEL CHANGES ............................................................................................. 2 TABLE OF CONTENTS ............................................................................................................... 2 PART I: HEALTH PROFESSIONAL INFORMATION ....................................................................... 4 1 INDICATIONS ................................................................................................................ 4 1.1 Pediatrics ................................................................................................................. 4 1.2 Geriatrics ................................................................................................................. 4 2 CONTRAINDICATIONS .................................................................................................. 4 3 SERIOUS WARNINGS AND PRECAUTIONS BOX ............................................................. 5 4 DOSAGE AND ADMINISTRATION .................................................................................. 5 4.1 Dosing Considerations ............................................................................................. 5 4.2 Recommended Dose and Dosage Adjustment .......... Preberite celoten dokument